Cargando…
P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431190/ http://dx.doi.org/10.1097/01.HS9.0000846712.74284.0f |
| _version_ | 1784779984321118208 |
|---|---|
| author | Lin, Y. Martin, T. Berdeja, J. G. Jakubowiak, A. Agha, M. Cohen, A. D. Deol, A. Htut, M. Lesokhin, A. Munshi, N. C. O’Donnell, E. Jackson, C. C. Yeh, T.-M. Banerjee, A. Zudaire, E. Madduri, D. Zhou, C. Pacaud, L. Usmani, S. Z. Jagannath, S. |
| author_facet | Lin, Y. Martin, T. Berdeja, J. G. Jakubowiak, A. Agha, M. Cohen, A. D. Deol, A. Htut, M. Lesokhin, A. Munshi, N. C. O’Donnell, E. Jackson, C. C. Yeh, T.-M. Banerjee, A. Zudaire, E. Madduri, D. Zhou, C. Pacaud, L. Usmani, S. Z. Jagannath, S. |
| author_sort | Lin, Y. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431190 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94311902022-08-31 P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY Lin, Y. Martin, T. Berdeja, J. G. Jakubowiak, A. Agha, M. Cohen, A. D. Deol, A. Htut, M. Lesokhin, A. Munshi, N. C. O’Donnell, E. Jackson, C. C. Yeh, T.-M. Banerjee, A. Zudaire, E. Madduri, D. Zhou, C. Pacaud, L. Usmani, S. Z. Jagannath, S. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431190/ http://dx.doi.org/10.1097/01.HS9.0000846712.74284.0f Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Lin, Y. Martin, T. Berdeja, J. G. Jakubowiak, A. Agha, M. Cohen, A. D. Deol, A. Htut, M. Lesokhin, A. Munshi, N. C. O’Donnell, E. Jackson, C. C. Yeh, T.-M. Banerjee, A. Zudaire, E. Madduri, D. Zhou, C. Pacaud, L. Usmani, S. Z. Jagannath, S. P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY |
| title | P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY |
| title_full | P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY |
| title_fullStr | P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY |
| title_full_unstemmed | P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY |
| title_short | P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY |
| title_sort | p961: ciltacabtagene autoleucel, a bcma-directed car-t cell therapy, in patients with relapsed/refractory multiple myeloma: 2-year post lpi results from the phase 1b/2 cartitude-1 study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431190/ http://dx.doi.org/10.1097/01.HS9.0000846712.74284.0f |
| work_keys_str_mv | AT liny p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT martint p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT berdejajg p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT jakubowiaka p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT agham p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT cohenad p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT deola p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT htutm p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT lesokhina p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT munshinc p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT odonnelle p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT jacksoncc p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT yehtm p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT banerjeea p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT zudairee p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT maddurid p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT zhouc p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT pacaudl p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT usmanisz p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT jagannaths p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study |